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TREATMENT OF LEUKEMIA

SUMMARY OF THE INVENTION

This invention relates to the novel compounds which are
derivatives of oxo-butenoic acid and their use alone or in
combination for treatment of human leukemia and claims
the benefit of priority to U.S. Provisional Application Ser.
No. 60/296,823 filed Jun. 8, 2001.

The objective of the present invention is to provide a
novel compound effective for treatment of human leukemia.
A preferred embodiment of the invention encompasses a
novel compound: 4-( 4-Ethoxy-phenyl)-2-(N'-fluoren-9ylidene-hydrazino )-2-hydroxy-4-oxo-butyric acid methyl
ester and compounds having the property of anti-cancer
activity against human leukemia comprising the use of
4-( 4-Ethoxy-pheny1)-2-(N'-fluoren-9-ylidene-hydrazino )-2hydroxy-4-oxo-butyric acid methyl ester (OF-13), and/or
4-Chloro-4-( 4-ethoxy-pheny 1)-2-(fluoren-9-y lidenehydrazono )-but-3-enoic acid methyl ester (3F-19) in humans
as therapeutic means for the eradication of leukemia from
the human's body.
Further objects and advantages of this invention will be
apparent from the following detailed description of presently
preferred embodiments which are illustrated structurally in
the accompanying drawings.

FIELD OF THE INVENTION
BACKGROUND OF THE INVENTION
Cancer is a global killer of humans with breast cancer and
colon cancer among the leaders with many other types
killing modest amounts of humans yearly.
Two blood cancers are of interest because there is no
known cure, i.e. myeloma and leukemia.
Leukemia is a type of cancer which is one of more than
100 diseases that have two important things in common. One
is that certain cells in the body become abnormal. Second is
that after this development, the human body keeps producing large numbers of these abnormal cells.
Leukemia is cancer of the blood cells and develops (as
noted) when the human body produces large numbers of
abnormal blood cells. In most types of leukemia, the abnormal cells are white blood cells. The leukemia cells usually
look different from normal blood cells, and they do not
function properly.
Since this cancer is complex in nature and not susceptible
to any specific therapy, there are a number of treatments
employed including chemotherapy when drugs are
employed, biological with the use of interferon, radiation
and bone marrow transplants.
Each year, nearly 27,000 adults and more than 2,000
children in the United States learn that they have leukemia
for which there is no cure only palliative treatment.
The U.S. patent literature has many disclosures of heterocyclic oxo-butenoic (crotonic) compounds:
Pamukci (U.S. Pat. No. 6,232,312) describes crotonic acid
derivatives (column 22, lines 43-58) for the treatment
of colonic polyps;
Jones et al (U.S. Pat. No. 6,121,450) discloses crotonic
acid derivatives (colunm 8, tine 34; colunm 78, line 24
and at example 34 as steroid modifiers in treating breast
cancer (colunm 1, lines 55-58);
Kalden, et al (U.S. Pat. No. 5,334,612) discloses compounds said to be useful for treating AIDS including
derivatives of carboxylic acid (colunm 9, line 31) and
pyrrolidine (colunm 7, line 24);
Brown (U.S. Pat. No. 6,066,670) describes an anti-viral
admixture containing crotonic acid for treating tumors
(see Abstract);
Harwell, et al (U.S. Pat. No. 5,580,896) discloses many
4-oxo-2-butenoic acid derivatives (colunm 13, lines
21-59; also in colunms 15+, examples 25,26,32,34,40,
43-46,77-79,97,99,103,106,), which are useful for
inhibiting colorectal cancer, i.e., colon cancer
(Abstract);
Giordani, et al (U.S. Pat. No. 5,580,890) discloses 4-oxo2-butenoic acid derivatives said to be useful for treatment of AIDS (colunm 1, line 8 and column 2, line 61;
and,
Yonemeto, et al (U.S. Pat. No. 6,083,985) recites a
number of anti-tumor or anti-AIDS agents that include
butenoic acid derivatives.
It appears from a review of the foregoing that the oxobutenoic derivatives of interest are not disclosed and thus
there is no report of their activity against human leukemia.
Consequently, there is a need for an anti-cancer drug for
humans that mitigates the above mentioned disadvantages of
current drug therapy and effectiveness against human leukemia.
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BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 illustrates structurally a chemical compound designated as OF-13.
FIG. 2 illustrates structurally a chemical compound designated as 3F-19.
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DESCRIPTION OF THE PREFERRED
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Before explaining the disclosed embodiments of the
present invention in detail, it is to be understood that the
invention is not limited in its application to the details of the
particular arrangement shown since the invention is capable
of other embodiments. Also, the terminology used herein is
for the purpose of description and not of limitation.
This application is directed to the use of the compounds
OF-13 and 3F-19, alone or in combination, which have been
structurally shown in FIGS. 1 and 2 respectively, to treat
human leukemia.
To facilitate a full understanding of the invention:
the compound designated as OF-13 is 4-(4-Ethoxypheny 1)-2-(N' -fluoren-9-y lidene-hydrazino )-2hydroxy-4-oxo-butyric acid methyl ester (claimed
herein) and,
the compound designated as 3F-19 is methyl 4-Chloro4-(4-ethoxy-pheny1)-2-( fluoren-9-y lidene-hydrazino )but-3-enoic acid methyl ester.
These compounds have very high activity against leukemia and a very low toxicity as Lethal Dose 50 (LD 50 ) in
animals. The percent activity and animal toxicity for each
compound is as follows: OF-13 (97% against human leukemia and LD 50 >1500 mg/kg), and 3F-19 (100% against
human leukemia and LD 50 >200 mg/kg).
PREPARATION OF (OF-13)
EXAMPLE 1
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The preparation of 4-( 4-Ethoxyphenyl)-2-(N'-fluoren-9ylidene-hydrazino )-2-hydroxy-4-oxobutyric acid methyl
ester (OF-13). A solution of 5.0 g (0.02 moles) of methyl
4-p-ethoxyphenyl-2-hydroxy-4-oxo-2-butenoate (1) and
3.88 g (0.02 moles) of fluorene-9-ylidene-hydrazine (2) in
80 mL of absolute benzene and absolute toluene (1: 1) was
refluxed for 1 hr 30 min with a Dean-Stark trap (the end of
the reaction was determined by TLC), cooled and the
precipitate was filtered and recrystallized from benzenediethyl ether-hexane mixture (1:3:2) to give 2.65 g (53%
yield) of colorless crystals with mp 114-116° C.
Solubility: highly soluble in DMSO, DMFA,
dichloroethane, acetonitrile, insoluble in hexane. The com-
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pound is not stable in solutions and decomposes quickly
when the solution is heated or stored for a long time with the
formation of OF-12.
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It is seen from the foregoing that (OF-13) is an intermediate
product during the synthesis of (OF-12).

PREPARATION OF (3F-19) (also included as a
"structure-use" in UCF-311B)
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The preparation of 4-Chloro-4-( 4-ethoxy-phenyl)-2(fluoren-9-ylidene-hydrazono )-but-3-enoic acid methyl
ester (3F-19) To the solution of 10 g (0.0026 moles) of
4-( 4-Ethoxy-phenyl)-2-(N'-fluoren-9-ylidene-hydrazino )-4oxo-but-2-enoic acid methyl ester (1) (synthesis was previously published by Konyukhova, N. A.; Krasnykh, 0. P.;
Aliev, Z. G.; Maslivets, A. N. Chemistry of Heterocyclic
Compounds (New York, N.Y., United States)(Translation of
Khimiya Geterotsiklicheskikh Soedinenii) (2001), 37(6),
779-780) in 5 mL of anhydrous benzene 0.3935 g (0.0031
moles) oxalyl chloride was added. The reaction mixture was
refluxed for 1 hour 40 min, cooled, precipitate was filtered
and recrystallized from absolute benzene to give 0.62 g
(54%) of yellow crystals, m.p. 163-163 (decamp).
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CYTOTOXICITY ASSAY
The activity against leukemia cancer cells of the compounds
(as earlier reported) was realized by the following procedure
which determines the inhibitory effect oftest samples on the
growth of human leukemia cancer cells (ATCC JURK). The
Jurkat cells are grown in RPMI 1640 media+10% Fetal
bovine serum+ 1% Antibiotic/Antimycotic+ 1% of HEPES
Buffer (1M)+1% Sodium Purivate (100 mM)+2.5% D-(+)
Glucose Solution for approximately 48 hours at 37° C./5%
co2 in the presence of the test in the presence of the test
compound.
Growth/Non-Growth of the cells (e.g., cell density) is
determined using Promega's MTS/PMS assay system. MTS
(3-( 4, 5-dimethyl thiazol-2-yl)-5-(3carboxymethoxypheny1)-2-(4-sulfopheny l)-2H-tetrazolium,
inner salt) is an aqueous compound that is reduced to soluble
formazan by the presence ofNADH formed by dehydrogenases present within the Jurkat cells. The absorbance of the
formazan can be measured at 490 nm and is directly proportional to the number of living cells present in the culture.
PMS (Phenazine Methosulfate) is added an electron coupiing reagent and greatly increases the rate of reduction.
To facilitate a full understanding of the procedure the
following definitions are offered:
Test wells-wells containing test sample and Diluted
Jurkat cells
Test values-absorbance of test wells
Blank wells-wells containing test sample and Jurkat
media (JURK-OlS); used to obtain background absorbance due to test sample
Blank values-absorbance of blank wells
Negative Control-maximal cell growth; results of test
samples will be expressed as a percent of the Negative
Control
Positive Control-known inhibitor of Jurkat cells; used to
validate assay system
Matrix-solvent that the samples are prepared/diluted in
Assay samples of similar origin and matrix (e.g., methanol extraction, methylene chloride extraction, water
soluble samples, etc.) together on the same plate in
order to reduce the number of steps performed per
plate.
Blank values will be determined for each sample to
account for any color contribution due to the sample
itself. These blank wells must contain the same amount
of sample plus Jurkat media (no cells). After completion of MTS/PMS reaction blank values will be subtracted from the test value to obtain a net absorbance
that will be used to calculate cell density.
All results are based upon a comparison to the Negative
Control value of the plate. The Negative Control must
contain the same amount of matrix (e.g., solvent) to offset
any destructive effect the matrix may have on the growth of
the Jurkat cells (allows for baseline values to be set).
For most samples, a Jurkat cell growth (initial density of
120,000 to 180,000 cells/ml) of approximately 48 hours
followed by and incubation of 2 hours with the MTS/PMS
Reagent is optimal.
In order to establish the accuracy of this assay a Positive
Control consisting of 50 µM Methotrexate should not
decrease the net absorbance to less than 90% of the Negative
Control (Jurkat cells are somewhat resistant to methotrexate)
is utilized.

toneal injection of2% solution of tested compound in starch
(the compound was dissolved in starch slime and injected)
on the basis of 0.1 ml of solution per 10 g of the animal
weight. Each dose was tested on the group of 6 animals that
were observed during 14 days period. (This method was
approved by the Pharmacology committee of Russian Ministry of Health and has been widely used since 1968.)
Averaged lethal dose (LD 50 ) of the compound was computed using results of experiments on 5-7 groups of animals
using method of Litchfield and Wilkinson. (Belenkii M. L.
"Elements of quantative determination of the pharmacological effect," Leningrad, 1963, 71 pages).

ANIMAL TOXICITY BIOASSAY
Acute toxicity was studied on white mice of both sexes
with weight ranging between 18-26 grams under intraperi-
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USE OF THE INVENTION FOR TREATMENT
OF LEUKEMIA CANCER
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The compounds of the invention which are useful for the
treatment of leukemia are 4-( 4-Ethoxy-phenyl)-2-(N'fluoren-9-ylidene-hydrazino )-2-hydroxy-4-oxo-butyric acid
methyl ester (OF-13), and 4-Chloro-4-(4-ethoxy-phenyl)-2(fluoren-9-ylidene-hydrazono )-but-3-enoic acid methyl
ester (3F-19) for in vivo use in humans as therapeutic means
for the eradication of leukemia can be used in a pharmaceutical composition comprising a non-toxic effective
amount of the referenced compounds, alone or together, or
a tautomeric form thereof or a pharmaceutically acceptable
salt thereof or pharmaceutically acceptable solvate thereof,
and a pharmaceutically acceptable carrier thereof.
For administration to man in the curative or prophylactic
treatment of human colon cancer in vivo dosages of compounds of the invention will generally be in the range of
from 5 to 500 mg daily for an average adult patient (70 kg).
Thus for a typical adult patient, individual tablets or capsules
contain from 2-500 mg of active compound, in a suitable
pharmaceutically acceptable vehicle or carrier, for administration in single or multiple doses, once or several times per
day. Exemplary dosages for intraveneous, buccal or sublingual administration will typically be within the range of
from 5-1000 mg per single dose as required. In practice the
physician will determine the actual dosing administration by
periodically monitoring the abnormal (generally white) cell
content of the blood which will be most suitable for an
individual patient and it will vary with the age, weight and
response of the particular patient. The above dosages are
exemplary of the average case but there can be individual
instances in which higher or lower dosage ranges may be
merited, and such are within the scope of this invention.
The maximum human one time administration dose for
the compound(s) of the invention appears to be 100 and 750
mg for 3F-19 and OF-13, respectiively.
For human use, the compounds of the invention can be
administered alone or jointly, but will generally be administered in admixture with a pharmaceutical carrier selected
with regard to the intended route of administration and
standard pharmaceutical practice. For example, they may be
administered orally, buccally or sublingually, in the form of
tablets containing excipients such as starch or lactose, or in
capasules or ovules either alone or in admixture with
excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents. The compounds may also
be injected parenterally, for example intraveneously,
intramuscularly, subcutaneously or intracoronarily. For
parenteral administration, they are best used in the form of
a sterile aqueous solution, which may contain other
substances, for example enough salts or glucose to make the
solution isotonic with blood.
The invention thus provides a method for the treatment of
leukemia in a human manimal which comprises administer-
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ing an effective, non-toxic, amount of a heterocyclic compound according to the invention or a tautomeric form
thereof and/or a pharmaceutically acceptable salt thereof
and/or a pharmaceutically acceptable solvate thereof, to a
leukemia invaded human mammal in need thereof.

released by virus-infected cells. They help normal cells to
make antiviral proteins. Interferons also help the body to
reduce leukemia cell proliferation (growth and
reproduction), while strengthening the body's immune
response. Unfortunately, though, this drug is not without
side effects. Possible IFN-related complaints include fevers,
chills, muscle aches, bone pain, headaches, concentration
difficulties, fatigue, nausea, vomiting, and general flu-like
symptoms when starting the drug.

ADVANTAGES OF THE INVENTION
Chemotherapy for leukemia is varied, because there are
many different forms of this disease. In general, though,
leukemia treatment relies on combination chemotherapy
with a number of different anticancer drugs. Such drugs
destroy cancer cells by preventing them from growing and
dividing rapidly. Unfortunately, a number of the body's
normal, noncancerous cells also divide rapidly and therefore
are harmed by chemotherapy.
Typical drug combination used in chemotherapy treatment of Acute Myelogenous Leukemia (AML) is a combination of daunorubicin (toxicity in mice LD50 26 mg kg- 1 )
with cytarabine (toxicity: in mice LD50 826 mg kg- 1 ).
These toxicities should be compared with the toxicity of
claimed compounds that lie in the range 1000-1500 mg kg- 1
in mice. It can be seen that the claimed compound has
toxicity at leas 50 times lower than daunorubicin and it is no
more toxic than cytarabine.
There is a variety of the side effects to this treatment.
Daunorubicin-myelosuppression (impaired bone marrow
function), cardiotoxicity (heart damage), gastrointestinal
effects; cytarabine-gastrointestinal effects (nausea,
vomiting, diarrhea), bleeding, fever.
Another approach to the leukemia treatment is by employing interferons. Interferons are a class of proteins that are
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It appears that the disclosed compounds create a means
for further development of anti-leukemia drugs with lower
toxicity and less side effects.
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While the invention has been described, disclosed, illustrated and shown in various terms of certain embodiments or
modifications which it has presumed in practice, the scope
of the invention is not intended to be, nor should it be
deemed to be, limited thereby and such other modifications
or embodiments as may be suggested by the teachings herein
are particularly reserved especially as they fall within the
breadth and scope of the claims here appended.
We claim:
1. A compound which is 4-( 4-Ethoxy-phenyl)-2-(N'fluoren-9-ylidene-hydrazino )-2-hydroxy-4-oxo-butyric acid
methyl ester.
2. A method of treating a human having leukemia which
comprises administering a non-toxic amount of a compound
according to claim 1 to said human.

* * * * *

